Physician

Phoebe Lynn Mellen, M.D.

According to 2025 Medicare claims, Phoebe Mellen, M.D. (NPI: 1144601097) practices ophthalmology in the Wheeling, WV-OH market, with the plurality of this provider's patient population coming from Belmont, OH. This provider's primary affiliated billing organization is RETINA VITREOUS CONSULTANTS INC. (NPI: 1063444123; TIN: 251492985) and primary practice location at 26059-1022. Mellen is affiliated with the ACO West Virginia (ACO ID: A3563), participating under the MSSP model.

Mellen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 524 traditional Medicare patients, billed 20,270 HCPCS/CPT codes, and received $1,412,883 in Medicare payments. The top billing code was J0178 (Injection, aflibercept, 1 mg). Part D data shows 318 prescription claims across 101 beneficiaries totaling $13,924 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 2 records totaling $2,154. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $16,147 to $1,412,883. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $6,794 and ending at $13,924. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$707K$1.4M2019 Medicare payment: $16,147 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $9,368 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $17,447 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $167,527 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $1,414,097 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $1,412,883 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019162190$16,147
2020151211$9,368
2021108123$17,447
20222691,088$167,527
202349813,093$1,414,097
202452420,270$1,412,883

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$24K$48K2015 Drug cost: $6,794 (USD; Tot_Drug_Cst)2016 Drug cost: $13,629 (USD; Tot_Drug_Cst)2017 Drug cost: $34,831 (USD; Tot_Drug_Cst)2018 Drug cost: $48,291 (USD; Tot_Drug_Cst)2019 Drug cost: $27,474 (USD; Tot_Drug_Cst)2020 Drug cost: $9,777 (USD; Tot_Drug_Cst)2021 Drug cost: $29,189 (USD; Tot_Drug_Cst)2022 Drug cost: $6,168 (USD; Tot_Drug_Cst)2023 Drug cost: $16,384 (USD; Tot_Drug_Cst)2024 Drug cost: $13,924 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20151540$6,794
201669170$13,629
2017228591$34,831
2018222862$48,291
2019138560$27,474
202067156$9,777
2021107307$29,189
202248109$6,168
202397273$16,384
2024101318$13,924

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
J0178Injection, aflibercept, 1 mg1631,071$661
99204New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more9898$106
67028Injection of drug into eye283882$88
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more365633$60
92134Imaging of retina472958$27

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate712,561$2,623
Bromfenac SodiumBromfenac Sodium17270$2,186
DifluprednateDifluprednate16453$1,603
Brimonidine TartrateBrimonidine Tartrate351,795$1,414
Ketorolac TromethamineKetorolac Tromethamine551,734$827

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.2$2,154Genentech USA, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Phoebe Lynn Mellen, M.D.?

Tedicare shows public-source Medicare data for Phoebe Lynn Mellen, M.D. (NPI 1144601097), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Phoebe Lynn Mellen, M.D. have ACO affiliation data?

Phoebe Lynn Mellen, M.D. is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563).

What billing organization is linked to Phoebe Lynn Mellen, M.D.?

Phoebe Lynn Mellen, M.D. is linked to RETINA VITREOUS CONSULTANTS INC. (billing NPI 1063444123) in the available physician profile data.

Does Phoebe Lynn Mellen, M.D. have Open Payments data?

Phoebe Lynn Mellen, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.